BTZ-043
- Generic Name
- BTZ-043
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C17H16F3N3O5S
- CAS Number
- 1161233-85-7
- Unique Ingredient Identifier
- G55ZH52P57
- Associated Conditions
- -
- Associated Therapies
- -
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- University College, London
- Target Recruit Count
- 2500
- Registration Number
- NCT06114628
- Locations
- 🇿🇦
TASK Eden, George, South Africa
🇹🇿NIMR Mbeya, Mbeya, Tanzania
🇿🇦TASK Brooklyn, Cape Town, South Africa
BTZ-043 Dose Evaluation in Combination and Selection
- Conditions
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Michael Hoelscher
- Target Recruit Count
- 90
- Registration Number
- NCT05926466
- Locations
- 🇹🇿
National Institute for Medical Research (NIMR-Mwanza),, Mwanza, Tanzania
🇿🇦TASK Applied Sciences Clinical Research Centre, Cape Town, South Africa
🇹🇿National Institute for Medical Research (NIMR-MMRC), Mbeya, Tanzania
PanACEA - STEP2C -01
- Conditions
- Interventions
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Michael Hoelscher
- Target Recruit Count
- 270
- Registration Number
- NCT05807399
- Locations
- 🇲🇼
Kamuzu College of Health Sciences (formerly College of Medicine), Blantyre, Malawi
🇹🇿Kilimanjaro Clinical Research Institute (KCRI), Moshi, Tanzania
🇺🇬Makerere University Lung Institute Limited, Kampala, Uganda
Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 128
- Registration Number
- NCT05382312
- Locations
- 🇿🇦
GSK Investigational Site, Cape Town, South Africa
BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)
- Conditions
- Interventions
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Michael Hoelscher
- Target Recruit Count
- 77
- Registration Number
- NCT04044001
- Locations
- 🇿🇦
TASK Applied Sciences Clinical Research Centre, Cape Town, South Africa
🇿🇦University of Cape Town Lung Institute (UCTLI), Cape Town, South Africa
A Single Ascending Dose Study of BTZ043
- Conditions
- Interventions
- First Posted Date
- 2018-07-18
- Last Posted Date
- 2019-03-07
- Lead Sponsor
- Michael Hoelscher
- Target Recruit Count
- 30
- Registration Number
- NCT03590600
- Locations
- 🇩🇪
Nuvisan, Neu-Ulm, Bavaria, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.